Dr. Lorenzo Maganuco
Physician
Dr. Lorenzo Maganuco graduated in Medicine and Surgery and later specialized in General Surgery at the University of Turin.
He has practiced in Turin at the San Giovanni Battista Hospital and the San Giovanni Bosco Hospital, and abroad at the Saint Roch Hospital in Nice, France.
From 2015 to 2025, he developed a specific interest in pancreatic pathology, deepening the discipline through training periods at European reference centers, including Heidelberg, Padua, and Peschiera del Garda. Since 2023, he has been involved in the robotic surgery program, applying that technology to pancreatic surgery as well.
He is a member of numerous scientific societies, including the Italian Association for the Study of the Pancreas (AISP), the European Pancreatic Club (EPC), the Padova Pancreas Club, the Wirsung APS, and the Association of Italian Hospital Surgeons (ACOI).
He was part of the working group for the drafting of the Diagnostic-Therapeutic Protocol for Pancreatic Cancer of the ASL City of Turin and Piedmont Region. He has been a member of the Regional Pancreatic Cancer Study Group for more than 10 years, contributing to the definition of the guidelines of the Piedmont and Aosta Valley Oncology Network.
He has authored and co-authored scientific publications and participated in numerous national and international congresses devoted to pancreatic diseases, including as a speaker.
At the Candiolo Institute, he was appointed as a senior specialist in pancreatic surgery and coordinator of the Interdisciplinary Care Group (ICG) Pancreas and Biliary Tract, for clinical and research activities on scientific protocols.
He is in charge of the Level II outpatient pancreatic surgery clinic, which is dedicated to the care of malignant neoplasms, neuroendocrine tumors and cystic diseases of the pancreas. He also participates in clinical and preclinical studies on pancreatic pathology, conducted within the Institute and in collaboration with other referral centers. He is particularly concerned with pancreatic adenocarcinomas, rare pancreatic tumors, pancreatic neuroendocrine tumors, pancreatic cystic disease (IPMN), benign pancreatic diseases, duodenal tumors, Vater’s papilla tumors, and colon tumors.